Get started
Author

Anna V. Ivanina Foureau

Observed names: Anna Ivanina Foureau, Anna Ivanina-Foureau
ORCID: 0000-0001-5701-2174
Observed ORCID: 0000-0001-5701-2174
OpenAlex ID: A5060754153
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
2024 · Manisha Bhutani, Myra Robinson, et al. · Blood Advances · 12
PDF
Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer
2022 · Anna V. Ivanina Foureau, Wei Sha, et al. · Translational Lung Cancer Research · 6
PDF
Phosphodiesterase Inhibition to Sensitize Non-Small-Cell Lung Cancer to Pemetrexed: A Double-Edged Strategy
2024 · Anna V. Ivanina Foureau, David M. Foureau, et al. · Cancers · 2
Abstract 3171: Multitargeted kinase inhibitor LCI139 overcomes chemotherapy resistance in patient-derived non small cell lung cancer organoids by harnessing intrinsic and extrinsic apoptosis
2026 · Anna Ivanina Foureau, Nadeem Wajih, et al. · Cancer Research
Abstract 369: A novel class of multitarget small molecule PI3K-CDK4/6-CDK9-AURAKA/B inhibitor harnesses Warburg effect against non-small cell lung cancer
2025 · Anna V. Ivanina Foureau, Cody C. McHale, et al. · Cancer Research
CAR-T Cell Subsets and Immune Repertoire Are Associated with Immune-Related Adverse Events and Efficacy after CD19 CAR T-Cell Therapy in B Cell Lymphoma
2024 · David M Foureau, Fei Guo, et al. · Blood
Abstract 1976: Targeting metabolism in non-small cell lung cancer (NSCLC) with the novel multitarget small molecule PI3K-CDK4/6-CDK9 inhibitor LCI139
2024 · Cody C. McHale, Anna V. Ivanina Foureau, et al. · Cancer Research
Abstract 281: Phosphodiesterase 8/9 inhibition to sensitize squamous non-small cell lung cancer (NSCLC) to pemetrexed (PMX): A double-edge strategy
2023 · Anna V. Ivanina Foureau, David M. Foureau, et al. · Cancer Research
Works count: 8
Citation count: 20
H-index: 2
I10-index: 1
Year
Topic
Type